Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease

Does the Montreal Cognitive Assessment (MoCA) identify cognitive impairment profiles in Parkinson's disease? An exploratory study

An important proportion of patients with Parkinson's Disease (PD) present signs of cognitive impairment, although this is heterogeneous. In an attempt to classify this, the dual syndrome hypothesis distinguishes between two profiles: one defined by attentional and executive problems with damage in anterior cerebral regions, and another with mnesic and visuospatial alterations, with damage in posterior cerebral regions. The Montreal Cognitive Assessment (MoCA) is one of the recommended screening tools, and one of the most used, to assess cognitive impairment in PD. However, its ability to specifically identify these two profiles of cognitive impairment has not been studied. The aim of this study was, therefore, to analyze the capacity of the MoCA to detect cognitive impairment, and also to identify anterior and posterior profiles defined by the dual syndrome hypothesis. For this purpose, 59 patients with idiopathic PD were studied with the MoCA and a neuropsychological battery of tests covering all cognitive domains. Results of logistic regression analysis with ROC (Receiver Operating Characteristic) curves showed that MoCA detected cognitive impairment and identified patients with a profile of anterior/attentional and executive deficit, with acceptable sensibility and specificity. However, it did not identify patients with a posterior/mnesic-visuospatial impairment. We discuss the reasons for the lack of sensitivity of MoCA in this profile, and other possible implications of these results with regards the usefulness of this tool to assess cognitive impairment in PD.

Prediction of Cognitive Decline in Parkinson's Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems

BACKGROUND

We aimed to predict Montreal Cognitive Assessment (MoCA) scores in Parkinson's disease patients at year 4 using handcrafted radiomics (RF), deep (DF), and clinical (CF) features at year 0 (baseline) applied to hybrid machine learning systems (HMLSs).

METHODS

297 patients were selected from the Parkinson's Progressive Marker Initiative (PPMI) database. The standardized SERA radiomics software and a 3D encoder were employed to extract RFs and DFs from single-photon emission computed tomography (DAT-SPECT) images, respectively. The patients with MoCA scores over 26 were indicated as normal; otherwise, scores under 26 were indicated as abnormal. Moreover, we applied different combinations of feature sets to HMLSs, including the Analysis of Variance (ANOVA) feature selection, which was linked with eight classifiers, including Multi-Layer Perceptron (MLP), K-Neighbors Classifier (KNN), Extra Trees Classifier (ETC), and others. We employed 80% of the patients to select the best model in a 5-fold cross-validation process, and the remaining 20% were employed for hold-out testing.

RESULTS

For the sole usage of RFs and DFs, ANOVA and MLP resulted in averaged accuracies of 59 ± 3% and 65 ± 4% for 5-fold cross-validation, respectively, with hold-out testing accuracies of 59 ± 1% and 56 ± 2%, respectively. For sole CFs, a higher performance of 77 ± 8% for 5-fold cross-validation and a hold-out testing performance of 82 + 2% were obtained from ANOVA and ETC. RF+DF obtained a performance of 64 ± 7%, with a hold-out testing performance of 59 ± 2% through ANOVA and XGBC. Usage of CF+RF, CF+DF, and RF+DF+CF enabled the highest averaged accuracies of 78 ± 7%, 78 ± 9%, and 76 ± 8% for 5-fold cross-validation, and hold-out testing accuracies of 81 ± 2%, 82 ± 2%, and 83 ± 4%, respectively.

CONCLUSIONS

We demonstrated that CFs vitally contribute to predictive performance, and combining them with appropriate imaging features and HMLSs can result in the best prediction performance.

Application of novel hybrid machine learning systems and radiomics features for non-motor outcome prediction in Parkinson's disease

Objectives.Parkinson's disease (PD) is a complex neurodegenerative disorder, affecting 2%-3% of the elderly population. Montreal Cognitive Assessment (MoCA), a rapid nonmotor screening test, assesses different cognitive dysfunctionality aspects. Early MoCA prediction may facilitate better temporal therapy and disease control. Radiomics features (RF), in addition to clinical features (CF), are indicated to increase clinical diagnoses, etc, bridging between medical imaging procedures and personalized medicine. We investigate the effect of RFs, CFs, and conventional imaging features (CIF) to enhance prediction performance using hybrid machine learning systems (HMLS).Methods.We selected 210 patients with 981 features (CFs, CIFs, and RFs) from the Parkinson's Progression-Markers-Initiative database. We generated 4 datasets, namely using (i), (ii) year-0 (D1) or year-1 (D2) features, (iii) longitudinal data (D3, putting datasets in years 0 and 1 longitudinally next to each other), and (iv) timeless data (D4, effectively doubling dataset size by listing both datasets from years 0 and 1 separately). First, we directly applied 23 predictor algorithms (PA) to the datasets to predict year-4 MoCA, which PD patients this year have a higher dementia risk. Subsequently, HMLSs, including 14 attribute extraction and 10 feature selection algorithms followed by PAs were employed to enhance prediction performances. 80% of all datapoints were utilized to select the best model based on minimum mean absolute error (MAE) resulting from 5-fold cross-validation. Subsequently, the remaining 20% was used for hold-out testing of the selected models.Results.When applying PAs without ASAs/FEAs to datasets (MoCA outcome range: [11,30]), Adaboost achieved an MAE of 1.74 ± 0.29 on D4 with a hold-out testing performance of 1.71. When employing HMLSs, D4 + Minimum_Redundancy_Maximum_Relevance (MRMR)+K_Nearest_Neighbor Regressor achieved the highest performance of 1.05 ± 0.25 with a hold-out testing performance of 0.57.Conclusion.Our study shows the importance of using larger datasets (timeless), and utilizing optimized HMLSs, for significantly improved prediction of MoCA in PD patients.

Diagnosis and management of Parkinson's disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) represent the second most common type of degenerative dementia in patients aged 65 years and older, leading to progressive cognitive dysfunction and impaired quality of life. This study aims to provide a consensus based on a systematic Brazilian literature review and a comprehensive international review concerning PDD and DLB. Moreover, we sought to report on and give recommendations about the best diagnostic approaches focusing on primary and secondary care. Based on the available data, we recommend clinicians to apply at least one brief global cognitive instrument to assess PDD, such as the Mini-Mental State Examination and preferably the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. Validated instruments to accurately assess functional abilities in Brazilian PD patients are still incipient. Further studies should focus on biomarkers with Brazilian cohorts.

Diagnosis and management of Parkinson’s disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

ABSTRACT Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) represent the second most common type of degenerative dementia in patients aged 65 years and older, leading to progressive cognitive dysfunction and impaired quality of life. This study aims to provide a consensus based on a systematic Brazilian literature review and a comprehensive international review concerning PDD and DLB. Moreover, we sought to report on and give recommendations about the best diagnostic approaches focusing on primary and secondary care. Based on the available data, we recommend clinicians to apply at least one brief global cognitive instrument to assess PDD, such as the Mini-Mental State Examination and preferably the Montreal Cognitive Assessment and the Addenbrooke’s Cognitive Examination-Revised. Validated instruments to accurately assess functional abilities in Brazilian PD patients are still incipient. Further studies should focus on biomarkers with Brazilian cohorts.

Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination

Several screening tests have been used for cognitive evaluation in Parkinson’s disease (PD).